Infliximab Decreases Resource Use Among Patients With Crohn's Disease
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Gastroenterology
Reference14 articles.
1. Inflammatory Bowel Disease
2. The Cost of Hospitalization in Crohn's Disease
3. A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease
4. Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
5. Infliximab in Crohn's Disease: First Anniversary Clinical Experience
Cited by 99 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Theoretical aspects of prescribing ustekinumab as first-line therapy for Crohn’s disease;Meditsinskiy sovet = Medical Council;2023-05-25
2. Economic burden related to fistulas or strictures among commercially insured patients with Crohn’s disease in the United States;Journal of Managed Care & Specialty Pharmacy;2023-04
3. Identification of the Most Effective Position for Ustekinumab in Treatment Algorithms for Crohn’s Disease;Clinical Gastroenterology and Hepatology;2021-10
4. Strictureplasty for Crohn’s disease of the small bowel in the biologic era: long-term outcomes and risk factors for recurrence;Techniques in Coloproctology;2020-04-18
5. The Role of TNF-α as a Proinflammatory Cytokine in Pathological Processes;The Open Dentistry Journal;2019-09-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3